vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and Tango Therapeutics, Inc. (TNGX). Click either name above to swap in a different company.
Tango Therapeutics, Inc. produced more free cash flow last quarter ($-29.9M vs $-37.5M).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies and novel immunotherapies for patients with hard-to-treat cancers. Its core pipeline targets genetic vulnerabilities in tumor cells, with key programs targeting mutations common across multiple solid tumor types, serving global oncology populations via in-house R&D and industry partnerships.
PRME vs TNGX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $0 |
| Net Profit | $-46.1M | — |
| Gross Margin | — | — |
| Operating Margin | -5800.5% | — |
| Net Margin | -5498.7% | — |
| Revenue YoY | -61.6% | — |
| Net Profit YoY | -9.0% | — |
| EPS (diluted) | $-0.22 | $-0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | $0 | ||
| Q3 25 | $1.2M | $53.8M | ||
| Q2 25 | $1.1M | $3.2M | ||
| Q1 25 | $1.5M | $5.4M | ||
| Q4 24 | $2.2M | $4.1M | ||
| Q3 24 | — | $11.6M | ||
| Q2 24 | $0 | $19.9M | ||
| Q1 24 | $591.0K | $6.5M |
| Q4 25 | $-46.1M | — | ||
| Q3 25 | $-50.6M | $15.9M | ||
| Q2 25 | $-52.6M | $-38.9M | ||
| Q1 25 | $-51.9M | $-39.9M | ||
| Q4 24 | $-42.3M | — | ||
| Q3 24 | — | $-29.2M | ||
| Q2 24 | $-55.3M | $-25.6M | ||
| Q1 24 | $-45.8M | $-37.9M |
| Q4 25 | -5800.5% | — | ||
| Q3 25 | -4406.0% | 26.2% | ||
| Q2 25 | -4787.2% | -1287.9% | ||
| Q1 25 | -3603.3% | -788.8% | ||
| Q4 24 | -2025.7% | — | ||
| Q3 24 | — | -283.3% | ||
| Q2 24 | — | -148.7% | ||
| Q1 24 | -8179.5% | -653.0% |
| Q4 25 | -5498.7% | — | ||
| Q3 25 | -4129.1% | 29.5% | ||
| Q2 25 | -4716.7% | -1221.4% | ||
| Q1 25 | -3568.8% | -739.5% | ||
| Q4 24 | -1936.6% | — | ||
| Q3 24 | — | -251.3% | ||
| Q2 24 | — | -128.6% | ||
| Q1 24 | -7743.0% | -585.9% |
| Q4 25 | $-0.22 | $-0.29 | ||
| Q3 25 | $-0.32 | $0.13 | ||
| Q2 25 | $-0.41 | $-0.35 | ||
| Q1 25 | $-0.40 | $-0.36 | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | — | $-0.27 | ||
| Q2 24 | $-0.46 | $-0.24 | ||
| Q1 24 | $-0.44 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $343.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $346.2M |
| Total Assets | $342.7M | $398.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $343.1M | ||
| Q3 25 | $71.4M | $152.8M | ||
| Q2 25 | $53.8M | $180.8M | ||
| Q1 25 | $91.9M | $216.7M | ||
| Q4 24 | $182.5M | $257.9M | ||
| Q3 24 | — | $293.3M | ||
| Q2 24 | $55.6M | $322.1M | ||
| Q1 24 | $94.2M | $343.6M |
| Q4 25 | $120.9M | $346.2M | ||
| Q3 25 | $161.8M | $160.0M | ||
| Q2 25 | $60.9M | $135.0M | ||
| Q1 25 | $106.9M | $166.8M | ||
| Q4 24 | $153.1M | $199.5M | ||
| Q3 24 | — | $229.2M | ||
| Q2 24 | $196.6M | $247.7M | ||
| Q1 24 | $243.8M | $264.5M |
| Q4 25 | $342.7M | $398.7M | ||
| Q3 25 | $385.0M | $210.1M | ||
| Q2 25 | $279.0M | $237.9M | ||
| Q1 25 | $328.2M | $274.3M | ||
| Q4 24 | $297.5M | $316.5M | ||
| Q3 24 | — | $352.4M | ||
| Q2 24 | $259.7M | $381.5M | ||
| Q1 24 | $311.4M | $406.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-29.7M |
| Free Cash FlowOCF − Capex | $-37.5M | $-29.9M |
| FCF MarginFCF / Revenue | -4480.4% | — |
| Capex IntensityCapex / Revenue | 34.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | $-139.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | $-29.7M | ||
| Q3 25 | $-35.0M | $-31.0M | ||
| Q2 25 | $-41.4M | $-36.5M | ||
| Q1 25 | $-48.9M | $-41.7M | ||
| Q4 24 | $16.2M | $-131.5M | ||
| Q3 24 | — | $-33.4M | ||
| Q2 24 | $-45.5M | $-23.6M | ||
| Q1 24 | $-67.7M | $-37.9M |
| Q4 25 | $-37.5M | $-29.9M | ||
| Q3 25 | $-35.3M | $-31.1M | ||
| Q2 25 | $-43.0M | $-37.1M | ||
| Q1 25 | $-51.3M | $-41.7M | ||
| Q4 24 | $14.5M | $-132.3M | ||
| Q3 24 | — | $-33.5M | ||
| Q2 24 | $-47.4M | $-23.9M | ||
| Q1 24 | $-70.0M | $-38.1M |
| Q4 25 | -4480.4% | — | ||
| Q3 25 | -2880.5% | -57.8% | ||
| Q2 25 | -3855.1% | -1167.7% | ||
| Q1 25 | -3526.8% | -774.3% | ||
| Q4 24 | 662.1% | -3213.2% | ||
| Q3 24 | — | -288.7% | ||
| Q2 24 | — | -120.4% | ||
| Q1 24 | -11849.6% | -588.0% |
| Q4 25 | 34.6% | — | ||
| Q3 25 | 20.2% | 0.3% | ||
| Q2 25 | 141.0% | 19.6% | ||
| Q1 25 | 166.6% | 0.9% | ||
| Q4 24 | 82.0% | 18.3% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | 393.2% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.95× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
